Does Vepotolizumab (POLIVY) and ULOVA have to be combined with chemotherapy?

Velpotuzumab (POLIVY) is marketed in China under the brand name Urova, and can be combined with bendamustine and rituximab(BR) for the treatment of relapse after at least two previous treatments /Patients with refractory diffuse large B-cell lymphoma (DLBCL), velpotuzumab also demonstrated significant clinical activity in patients with follicular lymphoma (FL).

Two clinical trials showed encouraging activity of velpotuzumab alone or in combination with rituximab in patients with severely pretreated diffuse large B-cell lymphoma and follicular lymphoma, but combinations with other active agents are needed to improve the depth and duration of response. Because peripheral neuropathy occurred in more than half of the patients treated with vepotuzumab 2.4 mg/kg, often resulting in treatment discontinuation, the maximum dose of vepotuzumab was set at 1.8 mg/kg in the dose-escalation portion of the subsequent combination trial.

Vepotuzumab, which is marketed in China, is a strictly controlled drug . Due to its short time on the market, it has not yet entered the scope of medical insurance. It is an injectable preparation. The price of 30 mg per box may be around 10,000 yuan. The price of the Hong Kong version of 140 mg per box may be around 60,000 yuan (the price may fluctuate due to exchange rates). Overseas The price of the European version of vepotuzumab on the market, Specifications140 mg per box, may be around 90,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of domestic original drugs are basically the same as those of foreign original drugs, and they are expensive. There are currently no generic versions of vepotuzumab on the market.